iShares Nasdaq US Biotechnology UCITS ETF
Reach European index investors at the moment they compare funds.
This billboard is available on the BTEC fund page. Brokers, issuers and fintechs — your message sits directly above the screener our readers use to pick their next ETF.
Documents & issuer links
Sample links — demo data- KID (Key Information Document)Two-page regulatory summary: risk score, costs, past performance
- ProspectusFull legal terms of the fund and its umbrella company
- FactsheetMonthly one-pager with performance, sectors and top holdings
- Annual reportAudited accounts, securities lending revenue and full holdings
- Index methodologyHow the benchmark selects, weights and rebalances constituents
- Full holdings (CSV)Every position with weights, published daily by the issuer
Always read the KID and prospectus on the issuer's own site before buying BTEC. ETFPanda is not affiliated with iShares.
Your product, in the feed our readers actually scan.
580 × 120 in-feed · native in-feed slot
Fund profile
Sample reference data- Benchmark index
- Nasdaq Biotechnology Index
- Index provider
- Nasdaq
- Replication
- Physical — full replication, optimised sampling on the long tail
- Rebalancing
- Annually
- Securities lending
- Not used by this share class
- Legal structure
- Open-ended ICAV / plc sub-fund
- Domicile
- Ireland
- UCITS
- Yes — UCITS V compliant
- SFDR classification
- Article 6 — no sustainability objective
- Income treatment
- Accumulating — income reinvested inside the fund
- Distribution frequency
- None — reinvested
- Currency hedging
- No — unhedged, currency risk is carried by the investor
- Withholding tax
- 15% US treaty rate on US dividends, no Irish withholding on payouts
- UK reporting status
- No
- Savings plans
- Available at most German and Austrian brokers
- Share class launch
- November 2016
- Fiscal year end
- 30 June
- Depositary / custodian
- State Street Custodial Services (Ireland)
Listings & identifiers
Sample cross-listings| Exchange | Ticker | Trading currency | Listing |
|---|---|---|---|
| Xetra | BTEC | EUR | Primary |
| SIX Swiss | BTEC | CHF | Cross-listing |
| Euronext Amsterdam | BTEC | EUR | Cross-listing |
Top holdings
Top 10 = 65.1% of the fund · sample data- 1Amgen10.41%
- 2Gilead Sciences9.26%
- 3Vertex Pharmaceuticals8.24%
- 4Regeneron7.34%
- 5Moderna6.53%
- 6Alnylam Pharmaceuticals5.81%
- 7BioMarin5.17%
- 8Incyte4.60%
- 9United Therapeutics4.10%
- 10Neurocrine3.65%
268 positions in total — the remaining 34.9% sits in the long tail.
Risk, return & total cost
Sample figures — not investment adviceWhat you actually pay each year
- Ongoing charge (TER)
- 0.35%
- Portfolio transaction costs
- 0.04%
- of which index licence fee
- 0.03%
- Estimated total cost
- 0.39%
Excludes your broker's commission and the bid–ask spread you pay on the way in and out.
Sticky placement — stays in view while readers scroll.
Book this spaceReach European index investors at the moment they compare funds.
This billboard is available on the foot of every fund page. Brokers, issuers and fintechs — your message sits directly above the screener our readers use to pick their next ETF.